Two scientists from Basel are trying to shed light on why myopia is impacting more and more people.

A Novartis experimental drug in clinical trial aims to block liver cancer growth

Talk to any cancer researcher or doctor today and what you hear is wonder and hope.

The best treatment for multifaceted diseases like NASH may be combinations of drugs.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges.

A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.

Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.